A single center, randomized, double blind, 3-treatment, 3-period, single-dose, cross over, comparative Phase-1 study to evaluate pharmacokinetics, safety, tolerability, and pharmacodynamics (PK/PD) of Stelis Teriparatide [rh-PTH (1-34)] with Forsteo and Forteo (teriparatide, Eli Lilly) in healthy volunteers following subcutaneous single dose administration of 20 g Teriparatide

Trial Profile

A single center, randomized, double blind, 3-treatment, 3-period, single-dose, cross over, comparative Phase-1 study to evaluate pharmacokinetics, safety, tolerability, and pharmacodynamics (PK/PD) of Stelis Teriparatide [rh-PTH (1-34)] with Forsteo and Forteo (teriparatide, Eli Lilly) in healthy volunteers following subcutaneous single dose administration of 20 g Teriparatide

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Quintiles; Stelis Biopharma
  • Most Recent Events

    • 29 Mar 2018 Planned End Date changed from 30 Apr 2018 to 29 Jun 2018.
    • 29 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 16 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top